1. Home
  2. PARK vs GANX Comparison

PARK vs GANX Comparison

Compare PARK & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park Dental Partners Inc.

PARK

Park Dental Partners Inc.

N/A

Current Price

$20.95

Market Cap

82.4M

Sector

Health Care

ML Signal

N/A

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.82

Market Cap

76.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PARK
GANX
Founded
1972
2017
Country
United States
United States
Employees
1212
N/A
Industry
Misc Health and Biotechnology Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.4M
76.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PARK
GANX
Price
$20.95
$1.82
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
33.1K
700.0K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.46
EPS
N/A
N/A
Revenue
N/A
$55,180.00
Revenue This Year
$7.06
N/A
Revenue Next Year
$6.17
N/A
P/E Ratio
$6.47
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.29
$1.41
52 Week High
$22.68
$4.34

Technical Indicators

Market Signals
Indicator
PARK
GANX
Relative Strength Index (RSI) 61.44 49.09
Support Level $17.27 $1.66
Resistance Level $21.65 $2.12
Average True Range (ATR) 1.42 0.14
MACD 0.27 0.01
Stochastic Oscillator 69.15 24.11

Price Performance

Historical Comparison
PARK
GANX

About PARK Park Dental Partners Inc.

Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: